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Abstract
Background: Data are limited on cancer outcomes in adolescents and young adults.
Methods: Based on data from the Western Australian Data Linkage System, this study modelled survival and excess
mortality in all adolescents and young adults aged 15–39 years in Western Australia who had a diagnosis of cancer in the
period 1982–2004. Relative survival and excess all-cause mortality for all cancers combined and for principal tumour
subgroups were estimated, using the Ederer II method and generalised linear Poisson modelling, respectively.
Results: A cancer diagnosis in adolescents and young adults conferred substantial survival decrement. However, overall
outcomes improved over calendar period (excess mortality hazard ratio [HR], latest versus earliest diagnostic period: 0.52,
trend p,0.0001). Case fatality varied according to age group (HR, oldest versus youngest: 1.38, trend p,0.0001), sex (HR,
female versus male: 0.66, 95% confidence interval [CI] 0.62–0.71), ethnicity (HR, Aboriginal versus others: 1.47, CI 1.23–1.76),
geographical area (HR, rural/remote versus urban: 1.13, CI 1.04–1.23) and residential socioeconomic status (HR, lowest
versus highest quartile: 1.14, trend p,0.05). Tumour subgroups differed substantially in frequency according to age group
and sex, and were critical outcome determinants.
Conclusions: Marked progressive calendar-time improvement in overall outcomes was evident. Further research is required
to disentangle the contributions of tumour biology and health service factors to outcome disparities between ethno-
demographic, geographic and socioeconomic subgroups of adolescents and young adults with cancer.
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Introduction
Cancers in adolescents and young adults (AYAs), commonly
defined as persons aged 15–39 years [1], have a distinctive
spectrum of pathology, different from that evident in children
(,14 years) and older adults. These malignancies comprise
a mixture of the non-epithelial cancers that commonly occur
during childhood and those of epithelial origin that account for
most cancers in older adults [1,2]. Furthermore, AYAs are not
homogeneous as a group, with substantial biological and
psychosocial differences pertinent to cancer outcomes evident
across the broad AYA age range.
Compared with children and older adults, patients in the AYAs
age group have reportedly experienced little or no improvement in
cancer survival in more than two decades, [1]. Possible contrib-
utory factors for the deficit in survival improvement include: delays
in seeking treatment, delays in recognition of malignancy by
physicians, lack of participation in clinical trials and low uptake of
private health insurance [3–5]. Fortunately, recent international
advocacy has led to better dissemination of research findings and
greater professional awareness concerning cancer in the AYA
population [6]. However, few empirical studies to date have
focused specifically on relative survival and excess mortality
experienced by AYA cancer patients. Such long-term survival
estimates are not only necessary for planning the healthcare
response to the cancer burden in this age-group, but also for
national and international comparisons between jurisdictions with
different environments and/or health care systems. Further, they
can serve as a foundation for appropriate surveillance, including
the management of long-term sequelae, such as late recurrence,
second primary cancers and other delayed disease-related and
iatrogenic complications [7]. In this paper, we estimate relative
survival ratios (RSR) and model excess mortality from malignan-
cies in AYAs, highlighting differences in outcomes according to
gender, age, socio-economic status, geographic location and
calendar period of diagnosis.
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Methods
Population and Data Source
Data on all individuals first diagnosed with invasive cancer or
lymphohaematopietic malignancy at 15–39 years of age during the
period 1982–2004 were extracted from the Western Australian
Data Linkage System (WADLS). Notification of all cancer
diagnoses has been a statutory requirement for all public and
private hospitals and pathology services in WA since 1981 [8], and
so the data reported here are considered to represent all eligible
individuals. Information obtained included demographic data
(date of birth, sex, Aboriginality, area/geozone of residence),
tumour-specific details (date and basis/modality of original
diagnosis, anatomical site, histology, behaviour, grade, date of
diagnosis and characteristics of subsequent malignancies) and vital
status. Active follow-up to December 31 2007 was performed
through linkage of data provided by the WA Cancer Registry
(WACR), the WA Mortality Register and the Australian National
Death Index. Malignancies were classified according to histolog-
ical origin, as described in the third edition of the International
Classification of Diseases for Oncology (ICD-O) [9], and further
characterized according to cancer subtypes based on the AYA
classification scheme published by The US Surveillance, Epide-
miology, and End Results Program (SEER) [10]. The SEER
subgroups were developed to better define the major cancer sites
that affect individuals aged 15–39 years [11].
Measurement of Co-morbidity, Area-based SES and
Residential Remoteness
Routine and unprecedentedly accurate geocoding of health
records is a unique feature of the WADLS. This enables
anonymised identification of the residential location of patients
(including categorisation of remoteness), from which socio-
economic status (SES) can be inferred. SES was measured using
the Index of Relative Socio-economic Disadvantage (IRSD),
which is based on Australian census data elements, including the
prevalence of low income, low educational attainment, unem-
ployment, rented dwellings, one-parent families, and other
measures of social disadvantage such as prevalence of poor
English language fluency [12]. Subjects were classified into four
SES groups, based on WA population quartiles (1st-25th centiles,
most disadvantaged; 76th-100th centiles, least disadvantaged). The
degree of residential remoteness was based on the Australian
Bureau of Statistics (ABS) Accessibility/Remoteness Index of
Australia (ARIA) codes, which use distances to population centres
as the basis for quantifying service access [13]. For the purpose of
this study, ARIA categories were collapsed into two groups; urban
(major cities) and rural & remote (inner regional, outer regional,
remote, and very remote), due to the smaller numbers of patients
in regional and remote areas. The Charlson Co-morbidity Index
(CCI), a weighted composite score of 17 different chronic
conditions, was used to adjust for the effects of co-morbidity [14].
Analysis
Relative survival ratio (RSR) was used to estimate disease-
specific survival. RSR is defined as the ratio of the observed
survival in the diseased individuals under study to the expected
survival of the underlying general population in WA according to
sex, age and calendar year of death. WA population estimates
were supplied by the ABS [15]. The major advantage of analysis
based on relative survival is that information on cause of death is
not required [16]. It provides a measure of excess mortality among
cancer patients, irrespective of whether or not deaths have been
medically certified as directly or indirectly cancer-induced/related
[16,17]. The Ederer II method, described elsewhere [18], was
used to calculate expected survival. Cancer cases classified in the
absence of histological confirmation, on the basis of death
certificate only (DCO) or other modality of diagnosis (e.g. hospital
record only), were excluded from the analysis. Generalised linear
models with Poisson error structures were used to model the excess
all-cause mortality associated with a diagnosis of cancer (up to 10
years after diagnosis) for all cancers combined and within each
principal diagnostic subgroup, including the effects of age, sex,
Aboriginality, co-morbidity, calendar period of diagnosis, length of
follow-up, SES, and area of residence. Poisson modelling was not
applied to subgroup analysis of bone sarcomas, due to small
sample size. Analyses were performed using SAS 9.2 [19].
Ethics
Ethics approval for this study was obtained from the University
of Western Australia Research Ethics Committee (reference
number: RA/4/1/2228). The Ethics Committee waived the need
for participants’ written informed consent as this was a minimal-
risk retrospective study, exclusively based on data extraction from
administrative databases, and it would not be feasible to get
patients’ consent for access to all charts. According to Australia
human research law, informed consent can be waived in cases for
which recording informed consent is not possible, provided that
a justification is registered and an Ethics Committee gives
approval. The data were analysed anonymously.
Results
Description of Cohort
There were 10,266 incident cases of malignant neoplasms
reported in WA among AYAs aged 15–39 years in 1982–2004.
Based on all-cause mortality, the proportions of AYA cancer
patients alive at 1, 5 and 10 years post-diagnosis were 91.8%,
75.6% and 49.8%, respectively. The median follow-up time was
8.2 years (interquartile range: 12 years). Figure 1 displays the
distribution of each diagnostic subgroup and selected carcinomas
by age group and sex, respectively. More than 98% of the cancer
registrations were histologically confirmed cases and 0.1% were
DCO diagnoses. The total of number of cases included in the
study, and the proportions of DCO diagnoses and cases verified
histologically are shown for each diagnostic subgroup in Table 1.
Relative Survival: Overall and within Diagnostic
Subgroups
Table 2 shows 5-year and 10-year RSR for the most recent
study period, 2000–2004, by diagnostic subgroup. Overall 5-year
RSR for AYAs diagnosed with any cancer was 0.84 (95% CI 0.82–
0.86) in males and 0.86 (0.85–0.88) in females. Favourable survival
prospects were observed for AYAs with melanoma (males:
RSR = 0.96, 0.92–0.96; females: RSR = 0.98, 0.96–0.99) and for
males with germ cell tumours (RSR = 1.00, 0.97–1.00). Among
females with germ cell tumours, average 5-year RSR exceeded
0.90 only in the youngest females (15–19 years). RSR for AYAs
with carcinomas was better in females compared with males (0.71,
0.67–0.76 versus 0.85, 0.83–0.87). AYAs diagnosed with lympho-
ma had encouraging prognoses with an overall 5-year RSR of
approximately 0.85. In contrast, diagnoses of leukaemias and
central nervous system (CNS) malignancies carried poor progno-
ses, with relatively low 5-year RSRs of approximately 0.60 and
0.50, respectively.
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Excess Mortality by Period of Diagnosis and Length of
Follow-up
Adjusted excess mortality hazard ratios in AYAs by diagnostic
subgroup and calendar period of diagnosis and time since
diagnosis are shown in Table 3. With the exception of the CNS
and soft tissue sarcoma tumour subtypes, excess mortality from
cancer decreased over calendar time (group effect p-value
,0.0001). AYA patients diagnosed in the period 2000–2004 with
any type of cancer were estimated to have a 52% (HR 0.50, CI
0.454–0.60.58) lower excess mortality compared with those
diagnosed in the earliest half-decade (1985–1989).
For all cancers combined and all studied cancer subgroups
except melanoma, the risk of dying decreased significantly with
duration of time after diagnosis. The annual risk of death from
melanoma remained stable throughout 5 years of follow-up
(Table 3).
Excess Mortality by Age-group
Considerable differences in the spectrum of cancers experienced
by the different age groups were noted (Figure 1). Table 4 shows
the risk of death by diagnostic group and age, sex, Aboriginal
status, location and social disadvantage. For all AYA cancers
combined, excess mortality increased with increasing age at
diagnosis. When diagnostic subgroups were analysed separately,
younger AYAs (aged 15–19 years) diagnosed with leukaemias had
significantly worse survival outcomes compared with older AYAs.
In other diagnostic groups (i.e., lymphoma, CNS and carcinomas)
for which there were a significant age differential, excess mortality
was associated with older age at diagnosis.
Excess Mortality by Sex
Survival for all cancers combined was poorer in males
compared with females (0.66, 0.62–0.71): females with lymphoma
(0.65, 0.49–0.87), soft tissue sarcoma (0.54, 0.35–0.83), melanoma
(0.53, 0.38–0.74) and carcinomas (0.51, 0.46–0.56) experienced
significantly lower excess mortality compared with males (Table 4).
In contrast, AYA females diagnosed with germ cell tumours (3.71,
2.17–6.36) experienced higher excess mortality compared with
their male counterparts, and higher excess mortality among
females with leukaemias approached statistical significance (1.26,
1.03–1.63).
Excess Mortality by Aboriginal Status
Non-Aboriginal AYAs comprised the majority (n = 9445, 92%)
of cancer cases. After adjusting for sex, age at diagnosis, co-
morbidity, locational disadvantage, SES, length of follow-up and
Figure 1. Distribution of each diagnostic groups and selected carcinomas displayed by age group.
doi:10.1371/journal.pone.0055630.g001
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year of diagnosis, Aboriginality significantly contributed to the risk
of death. Overall, Aboriginal AYAs experienced a higher excess
mortality (1.47, 1.23–1.76) compared with non-Aboriginal AYAs.
Among the diagnostic subgroups, Aboriginal AYAs diagnosed with
carcinomas experienced 25% significantly greater excess mortality
(1.25, 1.01–1.54) than their non-Aboriginal counterparts; and
those diagnosed with germ cell tumours experienced nearly seven
times higher excess mortality (6.7, 2.2–20.6). The results for the
other subgroups did not reach statistical significance.
Excess Mortality by Area of Residence and SES
AYAs living in rural and remote areas had an increased risk of
mortality compared with those who lived in urban areas (1.13,
1.04–1.23). However, among the diagnostic subgroups, the risk
was only significant for those diagnosed with carcinomas (1.38,
1.24–1.82). A significant gradient of increased mortality with
declining SES for all cancers combined was observed (HR, lowest
versus highest quartile: 1.14, trend p,0.05). Among the cancer
subgroups, the adjusted HRs were only significant for AYAs
diagnosed with leukaemias (trend p,0.001). Approximately 65%
of Aboriginal AYAs (versus 23% non-Aboriginal) resided in rural
and remote areas. Aboriginal AYAs in WA were over-represented
in the most socially disadvantaged categories, with less than 5% of
Aboriginal AYAs cancer patients (versus 27% non-Aboriginal) in
the highest quartile (least disadvantaged group).
Discussion
This paper reports estimates of long-term relative survival and
risk of excess mortality in AYAs diagnosed with cancer in WA,
using the current SEER classification for AYAs cancer subgroups.
Recently treated AYAs had a significantly lower risk of death than
those treated earlier in the study period. Older age at of diagnosis
was a predictor of poor prognosis for all cancers combined and for
lymphoma, CNS tumours and carcinomas indvidually. In general,
female AYAs had better survival outcomes compared with their
male counterparts. Aboriginality was identified as a poor prog-
nostic factor, particularly among AYAs diagnosed with germ cells
tumours. Our results reinforce the importance of both socio-
economic status and area of residence in the survival of AYAs
diagnosed with cancers.
Recently diagnosed AYAs (2000–2004) in this population were
estimated to have 50% lower excess mortality compared with
those diagnosed in 1980s. In particular, survival from leukaemias,
lymphomas, germ cell tumours, melanoma and carcinomas has
improved markedly over the last few decades. This is likely to
reflect the increasing availability of better diagnostic techniques
and more effective therapies. Male germ cell tumours and
melanomas presented the best prognoses with 5-year RSRs of
around 0.95 and 1.00, respectively. In a previous study, significant
improvements in outcomes from the treatment of germ cell
tumours had occurred mainly before the 1980s, coincident with
the widespread introduction of platinum-based treatment regi-
mens [20]. Recent improved survival is likely to reflect the fact
that, in most cases, germ cell tumours can be cured by adequate
treatment. Improvements in melanoma survival have been
attributed mainly to earlier cancer detection and increased
awareness among young Australians [21].
Of concern are the poor outcomes associated with CNS
tumours in this study. It is difficult to ascertain the reasons for
these. Unfortunately, WA Cancer Registry data on CNS tumours
do not include important predictors of survival, such as histological
categorisation (in a substantial minority of cases), extent of disease,
and molecular typing such as N-Myc expression. Epidemiological
research on CNS malignancies is inherently fraught, given the
biological heterogeneity of these tumours and the relative rarity of
any specific histologic subtype, as well as the challenges associated
with capture of pertinent data [5]. Large Multinational prospective
cohort studies, similar to the Childhood Cancer Survivor Study
[22], would facilitate understanding of CNS neoplasms and other
biologically complex cancer subgroups common among AYA.
The association of older age at diagnosis with poorer long-term
survival among AYAs diagnosed with lymphoma, CNS and
carcinomas is concordant with previous reports for this age group.
By contrast, in the case of leukaemia, survival was worse among
younger AYAs, aged 15–29 years compared with those older than
30 years. Past research has shown similar disparities, with children
and adolescents diagnosed with leukemia. Unlike children with
biologically similar leukaemias, younger AYAs are often admin-
istered adult rather than paediatric treatment regimens, which
may ultimately be less effective [23,24]. In multiple studies, there is
a consistent, large event-free survival and survival advantage for
young adult patients treated on paediatric versus adult protocols
[25]. However, these past findings do not explain the results of our
study.
Male AYAs diagnosed with germ cell tumours had markedly
reduced excess mortality compared with their female counterparts
had better survival outcomes than females, whereas males
diagnosed with lymphoma, soft tissue sarcoma, melanoma and
carcinomas had a worse prognosis. Sex did not significantly affect
prognosis in those diagnosed with CNS tumours, which is
consistent with previous studies [26]. Previous childhood cancers
studies have shown that girls with acute lymphoblastic leukaemia
generally have a slightly better prognosis than boys with this
disease [27,28]; possibly due to a different immuno-phenotype
distribution [29]. However, the modest sex differential favouring
male AYAs in this study is unexplained, and has not been
previously reported. Concordant with the current findings, sex has
been previously reported to be an independent prognostic factor











All Cancers 10266 (100) 0.7 98.6 0.06
Leukaemias 384 (3.7) 1.5 96.4 0
Lymphoma 806 (7.9) 1.4 97.9 0.1
CNS tumours 350 (3.4) 1.3 87.7 0
Bone sarcoma 148 (1.4) 1.4 98.8 0
Soft tissue
sarcoma
254 (2.4) 1.5 95.6 0.28
Germ cell
tumours
746 (7.2) 10.0 99.1 0
Melanoma 3127 (30.1 0.9 99.3 0.02
Carcinoma 4291 (41.8) 0.4 99.2 0.03
Thyroid 528 (5.1) 0.3 99.7 0
Breast 307 (12.7) – 99.5 0
Cervix uteri 699 (6.8) – 99.4 0
Colorectum 357 (3.5) 1.1 99.4 0
Other 610 (5.9) 0.7 98.5 0.1
Other Neoplasms160 (1.6) 0.7 79.5 1.6
doi:10.1371/journal.pone.0055630.t001
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for both non-Hodgkin’s [30] and Hodgkin’s lymphoma [31], with
male AYA patients having poorer outcomes than females.
Although female gender has been previously reported to be
independently associated with increased survival from melanoma
in older subjects, no clear explanation for this difference currently
exists [32]. Even less is known about the sex disparities for
melanoma survival in AYAs. The finding in our study may be
explained by higher attention of young women to their bodies [21]
and differing screening practices, even though a possibility of
hormonal or other sex-specific factors that play a role in
modulating the growth and metastatic potential of melanoma
[33] cannot be ruled out. The substantially reduced excess
mortality in males with germ cell tumours is likely attributable
to a prognostically more favourable spectrum of tumours, notably
including testicular germ cell cancers [34]. The converse excess
mortality gender disparity in the instance of carcinomas may be
attributed to the predominance among female AYAs of treatable
sex-specific carcinomas, such as those of the breast and cervix [2].
AYAs with cancer resident in rural and remote areas at the time
of diagnosis had an increased risk of mortality compared with their
urban-dwelling counterparts. Stratified analyses by diagnostic
group indicated a socioeconomic gradient in survival in those
diagnosed with carcinomas. The observed survival disparity for
carcinoma may reflect restricted access to optimal care and low
density of health care facilities in rural and remote Australia.
Previous studies in WA have indeed identified a service delivery
gap for rural residents diagnosed with carcinomas of the colon and
rectum [35], breast [36] and lung [36]. Treatment at private
hospitals, which are concentrated in urban areas, has also been
identified as an independent predictor of survival for colorectal
[35], breast [36] and lung [36] cancers.
Table 2. 5- and 10-year relative survival ratio for the most recent diagnosis period, 2000–2004.a
Males Females
5-yr RSR (95% CI) 10-yr RSR (95% CI) 5-yr RSR (95% CI) 10-yr RSR (95% CI)
All Cancers 15–19 0.85 (0.79, 0.90) 0.80 (0.73, 0.85) 0.92 (0.85, 0.95) 0.81 (0.71, 0.88)
20–29 0.89 (0.86, 0.92) 0.88 (0.84, 0.90) 0.87 (0.83, 0.90) 0.79 (0.75, 0.83)
30–39 0.81 (0.78, 0.83) 0.75 (0.71, 0.78) 0.85 (0.83, 0.87) 0.81 (0.79, 0.82)
15–39 0.84 (0.82, 0.86) 0.78 (0.75, 0.81) 0.86 (0.85, 0.88) 0.81 (0.78, 0.83)
Leukaemias 15–19 0.64 (0.52, 0.86) 0.53 (0.30, 0.72) 0.62 (0.49, 0.85) 0.45 (0.25, 0.67)
20–29 0.73 (0.57, 0.83) 0.57 (0.33, 0.72) 0.69 (0.53, 0.94) 0.62 (0.38, 0.71)
30–39 0.57 (0.44, 0.82) 0.54 (0.34, 0.73) 0.54 (0.34, 0.83) 0.44 (0.28, 0.63)
15–39 0.62 (0.46, 0.75) 0.55 (0.35, 0.67) 0.61 (0.33, 0.87) 0.46 (0.36, 0.54)
Lymphoma 15–19 0.92 (0.73, 0.99) 0.93 (0.72, 0.98) 0.97 (0.94, 0.99) 0.94 (0.65, 0.99)
20–29 0.89 (0.73, 0.96) 0.94 (0.82, 0.98) 0.85 (0.61, 0.95) 0.83 (0.63, 0.93)
30–39 0.81 (0.67, 0.88) 0.71 (0.58, 0.82) 0.87 (0.72, 0.94) 0.83 (0.69, 0.91)
15–39 0.85 (0.77, 0.90) 0.81 (0.71, 0.88) 0.84 (0.74, 0.91) 0.85 (0.74, 0.92)
Melanoma 15–19 0.62 (0.34, 0.89) 0.47 (0.15, 0.85) 0.57 (0.23, 0.88) 0.46 (0.11, 0.80)
20–29 0.66 (0.38, 0.83) 0.51 (0.29, 0.69) 0.52 (0.26, 0.73) 0.33 (0.15, 0.50)
30–39 0.56 (0.35, 0.78) 0.35 (0.19, 0.52) 0.61 (0.26, 0.84) 0.45 (0.24, 0.65)
15–39 0.55 (0.41, 0.71) 0.42 (0.25, 0.57) 0.52 (0.36, 0.65) 0.43 (0.22, 0.63)
CNS 15–19 0.76 (0.13, 0.97) 0.67 (0.20, 0.91) 0.97 (0.94, 1.00) 0.84 (0.27, 0.98)
20–29 0.87 (0.57, 0.97) 0.66 (0.38, 0.83) 0.99 (0.89, 1.00) 0.72 (0.26, 0.93)
30–39 0.87 (0.63, 0.96) 0.65 (0.39, 0.82) 0.76 (0.51, 0.90) 0.53 (0.20, 0.78)
15–39 0.83 (0.67, 0.92) 0.65 (0.43, 0.81) 0.81 (0.64, 0.91) 0.70 (0.38, 0.88)
Soft tissue 15–19 0.95 (0.79, 0.99) 0.94 (0.74, 0.99) 0.92 (0.72, 0.98) 0.72 (0.41, 0.89)
20–29 0.99 (0.88, 1.00) 0.98 (0.92, 1.00) 0.85 (0.60, 0.97) 0.80 (0.20, 0.97)
30–39 0.91 (0.80, 0.96) 1.00 (0.94, 1.00) 0.84 (0.27, 0.98) 0.84 (0.27, 0.97)
15–39 1.00 (0.97, 1.00) 0.94 (0.87, 0.97) 0.87 (0.57, 0.97) 0.73 (0.46, 0.88)
Germ Cell 15–19 0.95 (0.81, 0.99) 0.95 (0.84, 0.98) 0.97 (0.93, 0.99) 0.93 (0.69, 0.99)
20–29 0.97 (0.93, 0.99) 0.97 (0.93, 0.99) 0.98 (0.95, 1.00) 0.98 (0.95, 1.00)
30–39 0.96 (0.90, 0.97) 0.93 (0.89, 0.96) 0.98 (0.95, 0.99) 0.98 (0.95, 1.00)
15–39 0.96 (0.92, 0.96) 0.95 (0.91, 0.97) 0.98 (0.96, 0.99) 0.97 (0.94, 0.99)
15–19 0.88 (0.60, 0.97) 0.65 (0.38, 0.83) 0.97 (0.79, 1.00) 0.75 (0.48, 0.90)
Carcinomas 20–29 0.80 (0.70, 0.87) 0.80 (0.70, 0.88) 0.86 (0.81, 0.90) 0.72 (0.64, 0.78)
30–39 0.68 (0.62, 0.73) 0.60 (0.54, 0.66) 0.84 (0.81, 0.87) 0.78 (0.75, 0.81)
15–39 0.71 (0.67, 0.76) 0.62 (0.56, 0.68) 0.85 (0.83, 0.87) 0.76 (0.73, 0.79)
aBone Sarcoma not included among subgroup analyses; CI: confidence intervals.
doi:10.1371/journal.pone.0055630.t002
Cancer Survival and Mortality for Young People
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55630
Our study is the first to examine socioeconomic impacts on
survival in Australian AYAs with cancer, demonstrating higher
excess mortality in AYAs living in socio-economically disadvan-
taged groups, regardless of area of residence. The effects of SES on
prognosis for AYAs were significant for all cancers combined.
However, when groups were analysed individually, a significant
gradient was detected only for leukaemias. A similar pattern for
leukaemias has been found in another study [37]. These measured
effects of SES on survival may be a proxy for differences in health
awareness and behaviours and/or access to health services,
resulting in delayed presentations and thereby diagnoses at more
advanced stages of disease. Accordingly, individuals with the
highest SES have better access to private healthcare insurance
[38]. AYAs have comparatively low health insurance coverage,
with lack of private insurance shown to be associated with worse
survival for of carcinomas (breast, colorectal) that commonly occur
in AYAs.
Our study also revealed that young Aboriginal people diagnosed
with cancer experienced worse survival outcomes compared with
non-Aboriginal AYAs. Notably, Aboriginal AYAs diagnosed with
germ cell tumours experienced nearly seven-times greater
mortality compared with non-Aboriginal AYAs. Although, there
is risk of important residual confounding by location due to our
stratified analysis of locational disadvantage (urban vs. rural &
Table 3. Adjusted excess mortality hazard ratios by diagnostic group, calendar period of diagnosis and years of follow-up, 1982–
2004.a,b




1990–1994 1995–1999 2000–2004 Year 2 Year 3 Year 4 Year 5
All cancers 0.87 (0.44, 0.85) 0.62 (0.52, 0.73) 0.52 (0.45, 0.60) { 0.64 (0.59, 0.71) 0.38 (0.34, 0.43) 0.31 (0.27, 0.35) 0.22 (0.19, 0.26) {
Leukaemia 1.01 (0.43, 1.37) 0.94 (0.21, 1.67) 0.61 (0.38, 1.00) { 0.73 (0.54, 0.10) 0.49 (0.34, 0.72) 0.36 (0.23, 0.56) 0.23 (0.13, 0.40) {
Lymphoma 0.87 (0.59, 1.34) 0.62 (0.43, 0.97) 0.48 (0.30, 0.84) { 0.59 (0.42, 0.83) 0.35 (0.23, 0.53) 0.12 (0.06, 0.24) 0.22 (0.13, 0.37) {
CNS 0.89 (0.47, 1.57) 1.00 (0.60, 1.71) 1.04 (0.66, 1.74) 0.73 (0.53, 0.99) 0.35 (0.23, 0.54) 0.40 (0.26, 0.61) 0.32 (0.19, 0.52) {
Soft tissue 1.16 (0.70, 2.14) 0.78 (0.29, 1.90) 0.62 (0.32, 1.26) 0.97 (0.62, 1.51) 0.17 (0.07, 0.41) 0.29 (0.14, 0.60) 0.31 (0.15, 0.64) {
Germ cell 0.40 (0.26, 0.85) 0.36 (0.16, 0.95) 0.21 (0.09, 0.39) { 0.70 (0.35, 1.39) 0.38 (0.16, 0.90) 0.19 (0.06, 0.64) 0.05 (0.003, 0.82) {
Melanoma 0.91 (0.80, 1.37) 0.37 (0.26, 0.53) 0.31 (0.12, 0.64) { 0.88 (0.55, 1.41) 0.64 (0.38, 1.09) 0.71 (0.43, 1.19) 0.87 (0.54, 1.41)
Carcinoma 0.88 (0.75, 1.04) 0.78 (0.66, 0.82) 0.59 (0.50, 0.70) { 0.65 (0.58, 0.74) 0.43 (0.37, 0.50) 0.35 (0.29, 0.41) 0.23 (0.18, 0.27) {
amodel also adjusted for sex, Aboriginal status, age at diagnosis, years of follow-up; ARIA, IRSD and Charlson Index; {: highly significant group effect (p,0.0001); {:
significant group effect (0.001,p,0.05).b Poisson model was not applied to bone sarcomas because of instability and lack of convergence in the regression model.
doi:10.1371/journal.pone.0055630.t003
Table 4. Adjusted excess mortality hazard ratios by diagnostic group and sex, Aboriginal status, age, location and social
disadvantage, 1982–2004.a







Reference: 4th quartile (least
disadvantaged)
Female Yes 20–29 30–39 Rural/remote
1st quartile
(most) 2nd quartile 3rd quartile




1.38 (1.21, 1.58) { 1.13 (1.04, 1.23) { 1.14 (1.04, 1.26) 1.03 (0.93, 1.13) 1.01 (0.92, 1.16) {




0.74 (0.52, 1.06) { 0.99 (0.70, 1.39) 1.23 (0.85, 1.76) 1.18 (0.82, 1.71) 1.01 (0.71, 1.44) {




2.13 (1.39, 3.25) { 1.10 (0.80, 1.51) 1.07 (0.74, 1.55) 1.29 (0.91, 1.83) 1.30 (0.91, 1.84)




1.60 (1.09, 2.35) { 1.09 (0.82, 1.46) 1.14 (0.82, 1.59) 1.07 (0.78, 1.49) 0.97 (0.52, 1.11)




1.13 (0.65, 1.95) 1.21 (0.72, 2.03) 1.47 (0.83, 2.59) 1.41 (0.78, 2.57) 0.92 (0.53, 1.61)




1.03 (0.61, 1.89) 1.08 (0.58, 2.01) 0.83 (0.42, 1.65) 1.59 (0.84, 3.07) 1.14 (0.55, 2.34)
Melanoma 0.53 (0.38, 0.74) { 3.63 (0.50,
26.2)
1.19 (0.67,.10) 1.28 (0.74, 2.21) 1.09 (0.83, 1.43) 1.21 (0.87, 1.69) 1.09 (0.79, 1.50) 1.08 (0.79, 1.47)




1.80 (1.30, 2.50) { 1.38 (1.24, 1.82) { 0.99 (0.87, 1.12) 1.07 (0.94, 1.21) 0.98 (0.86, 1.12)
amodel also adjusted for years of follow-up, calendar period and Charlson Index; {: highly significant group effect (p,0.0001); {: significant group effect
(0.001,p,0.05).
doi:10.1371/journal.pone.0055630.t004
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remote), the difference in survival by Aboriginality persisted after
adjustment for area-based SES and locational disadvantage). This
would suggest the possibility of important biological or other
unknown factors that contribute to worse survival in Aboriginal
males. However, it is difficult from our analysis alone to determine
whether differences were due to biology or other possible factors
such as differential access to adequate treatment or and health
behaviours.
Strengths and Weaknesses
A major strength of this study is its use of routinely-collected,
whole-population data from the WADLS, which has undergone
extensive validation, with false-positives and false-negatives of
subject identification shown to be ,1%. Rigorous characterisation
of the cancers and careful follow-up were important features of the
WACR. Rigorous procedures are implemented to ensure that
cancer ascertainment is as complete as possible; cases are identified
from multiple sources. In relation to the main indicator of data
quality, namely, the modality of diagnosis (microscopic confirma-
tion or death certificate only) [39,40], WACR data is superior to
the European average published in EUROCARE-4 [46]. Micro-
scopic confirmation is a particularly important indicator of data
quality because histology is the ‘gold standard’ for cancer diagnosis
and histological type is the primary basis for cancer classification.
In our study, a very high proportion of cases were confirmed
microscopically (.98%). The proportion of microscopically
verified cases varied according to AYA category, and was lowest
for CNS malignancies (88%). In the WACR database, ,0.1% of
tumour records were classified as DCO [41]. In our AYA series,
DCO cases were rare (0.6% overall) with the exception of soft
tissue sarcomas (0.3%).
Given the relative homogeneity of the Australian health system,
and that WA is socio-demographically representative of Australia
as a whole, these results may be considered to reflect AYA cancer
outcomes nationally [42]. Clearly there are caveats on the
applicability to other jurisdictions of our data on the relationship
between geographical remoteness and outcomes, given that WA is
characterised by singularly low population density and unusually
long distances between rural/remote locations and urban specialist
cancer facilities. The important issue of whether mean survival
figures by geographical region are representative of wider areas as
a whole has been addressed elsewhere [43,44]. Additionally, as our
data are derived from the relatively small WA population,
outcomes of infrequent tumours, such as bone sarcomas, could
not be properly examined. Hence survival probabilities and
comparisons, especially for rare cancers, were susceptible to
chance variation.
A major limitation of the present study was the lack of cancer
staging data. We were unable to make a more in-depth assessment
of differences in survival by stage at diagnosis because this
information is not routinely collected by the WACR. Additional
limitations include the potential for residual socio-economic
confounding, as estimation of SES was based on the locality of
residence at diagnosis, with measurement at the individual level
not possible from de-identified linked data. Our approach may not
have accurately captured some factors that contribute to cancer
survival, such as healthy living environments, and adequate
medical care. Additionally, AYAs are a heterogeneous group by
virtue of transitioning through developmental life stages: some are
dependent on parents and relatives while others provide for
families of their own. As such, measuring SES as a single point-in-
time geographical area composite variable may inadequately
summarize an individual patient’s life-course social and financial
circumstances. On the other hand, only focusing on individuals
ignores the broader issues of area contextual effects on health, such
as community resources for healthy living.
An RSR estimate reflects the ratio of the observed survival
divided by the expected survival of a cohort of the general
population possessing similar characteristics with respect to age at
calendar time/era and sex. Other major advantages of working
with RSR estimates include the fact that data on cause of death
are not required, which circumvents difficulties with inaccuracy or
lack of death certification. However, this apparent strength may
present important limitations for our AYA cohort. Young adults
aged 20–39 years are the age group at the highest risk of acquiring
HIV infection [45]; and infected individuals are at increased risk of
developing Kaposi sarcoma, lymphoma and invasive cervical
cancer, ‘‘acquired immunodeficiency syndrome (AIDS)-defining
malignancies’’, in this context. These cancers are more aggressive
when occurring in HIV-infected patients, and result in poor
prognosis. In our study, we did not ascertain HIV status and based
our analysis on all-cause mortality without incorporating cause of
death data, and were therefore unable to delineate between AIDS-
related deaths and other deaths. Nonetheless, we do not expect
AIDS-related deaths to have influenced our survival estimates.
Likely due to WA’s geographical isolation, HIV infection is
uncommon and the incidence of AIDS and related deaths is
generally lower than in the rest of Australia and most in-
dustrialized countries. By mid-2007, only 475 diagnoses of AIDS
and 324 deaths following AIDS were reported in WA since 1981
[45].
Conclusion
Survival of AYAs diagnosed with cancer has generally increased
over time. Despite favourable survival prognoses for some cancers
in AYAs, there remains considerable disparity in cancer outcomes
between different socio-demographic categories of AYA patients as
well as substantial variation in the outcomes from different
categories of cancer. Survival differentials identified in this study,
particularly in relation to testicular germ cell tumours, should be
investigated in greater depth; in order to distinguish instances in
which improvements in survival can be attained through pro-
moting equity of service access from those requiring novel
therapeutic strategies directed towards distinctive aspects of
tumour biology.
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